文献速递临床免疫临床生化

ST2浊度免疫分析法与酶联免疫吸附法在射血分数降低心衰患者生存预测中的比较

Suppression tumorigenicity 2 (ST2) turbidimetric immunoassay compared to enzyme-linked immunosorbent assay in predicting survival in heart failure patients with reduced ejection fraction.
PubMed 文献 · Clin Chim Acta · 2020-09-12

该研究在721例射血分数降低的心衰患者中比较了新型ST2浊度免疫分析法(TIA)与酶联免疫吸附法(ELISA)的相关性及预后价值。结果显示两种方法高度相关(Spearman r=0.77),对全因死亡的预测效应相似,TIA可作为ELISA的替代方法。

要点

  • ST2的TIA与ELISA法相关性良好(r=0.77),比例差异无统计学意义。
  • 两种方法测得的ST2均与全因死亡显著相关,效应量相似。
  • 在MAGGIC评分基础上,两种ST2均能小幅提升AUC,但加入NTproBNP后提升不显著。

核心结论

  • 新型ST2浊度免疫分析法与ELISA高度相关,并提供相似的風險分層能力。

主要发现

  • 两种方法间Spearman相关系数为0.77;非参数回归显示斜率=0.97,系统差异为3.2 ng/mL。
  • 单变量分析中,TIA和ELISA测得的ST2均与生存显著相关,HR分别为4.46和3.50(均p<0.001)。
  • 调整MAGGIC评分后,两者仍显著,且较单独MAGGIC评分改善AUC:MAGGIC AUC=0.757,TIA+MAGGIC AUC=0.786(p=0.025),ELISA+MAGGIC AUC=0.793(p=0.033)。
  • 同时纳入MAGGIC和NTproBNP的模型中,两种ST2仍显著但未改善AUC。

临床怎么用

  • TIA法可在常规生化分析仪上运行,有望替代ELISA用于心衰患者的ST2检测和风险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Suppressor of tumorigenicity 2 (ST2) is a powerful marker of prognosis and treatment response in heart failure (HF), however, it is an enzyme-linked immunosorbent assay (ELISA) which may be cumbersome and costly. A turbidimetric immunoassay (TIA) that can run on common chemistry analyzers could overcome this. We studied a novel TIA for ST2, comparing it to commercial ST2 (ELISA). METHODS: Patients age ≥ 18 years meeting Framingham definition for HF were enrolled in a prospective registry (Oct 2007 - March 2015) at Henry Ford Hospital and donated blood samples. Participants with reduced ejection fraction (<50%) and available plasma samples were included and valid ST2 measurements were obtained on the same sample using both TIA and ELISA (N = 721). The primary endpoint was all cause death. Correlation between the methods was quantified. The association with survival was tested using unadjusted and adjusted (for MAGGIC score and NTproBNP) Cox models and comparing the Area Under the Curve (AUC). RESULTS: The inter-assay Spearman correlation coefficient was 0.77. Nonparametric regression showed no significant proportional difference (slope = 0.97) and a very small systematic difference (3.2 ng/mL). In univariate analyses, both TIA and ELISA ST2 were significant associates of survival with similar effect sizes (HR 4.46 and 3.50, respectively, both p < 0.001). In models adjusted for MAGGIC score, both ST2 remained significant in Cox models and incrementally improved AUC vs. MAGGIC alone (MAGGIC AUC = 0.757; TIA + MAGGIC AUC = 0.786, p = 0.025; ELISA + MAGGIC AUC = 0.793, p = 0.033). In models with both MAGGIC and NTproBNP included, both ST2 still remained significant but did not improve AUC. CONCLUSIONS: A novel TIA method for ST2 quantification correlates highly with ELISA and offers similarly powerful risk-stratification.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Aurora L, Peterson E, Gui H, et al. Suppression tumorigenicity 2 (ST2) turbidimetric immunoassay compared to enzyme-linked immunosorbent assay in predicting survival in heart failure patients with reduced ejection fraction. Clin Chim Acta. 2020. PMID: 32926842. doi:10.1016/j.cca.2020.08.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。